Education
About Us
Working with TipRanks
Follow Us
Daiichi Sankyo Company Limited (JP:4568)
:4568
RESEARCH TOOLSreports
4568 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥3,366.00 - ¥6,257.00
Previous CloseN/A
Volume4.34M
Average Volume (3M)5.70M
Market Cap
$6.82T
Enterprise Value¥7.64T
Total Cash (Recent Filing)¥126.42B
Total Debt (Recent Filing)¥255.35B
Price to Earnings (P/E)28.1
Beta1.01
Next Earnings
Apr 24, 2025EPS Estimate
19.69Last Dividend Ex-Date
Mar 28, 2025Dividend Yield1.74%
Share Statistics
EPS (TTM)129.03
Shares Outstanding1,908,322,100
10 Day Avg. Volume5,796,980
30 Day Avg. Volume5,696,750
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,633.31Price Target Upside55.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Daiichi Sankyo Company News
PremiumCompany Announcements
Daiichi Sankyo Reports Robust Q3 Earnings Performance
---
Bulls Say, Bears Say
Bulls Say
Drug ApprovalFDA has approved anticancer candidate Dato-DXd for breast cancer, which is considered a positive surprise by the market.
Market ExpectationsExpectations for Dato's first US approval for breast cancer are high, supported by approval from Japanese authorities.
Bears Say
Clinical Study ResultsDaiichi's shares have declined by about 1/3 since the company reported disappointing Ph2 data from the TROPION-Lung01 study.
Financial PerformanceDaiichi's shares have declined by about 1/3 since the company reported disappointing data from a lung cancer study.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
12.32%
Mutual Funds
0.02% Other Institutional Investors
78.79% Public Companies and
Individual Investors
4568 FAQ
What was Daiichi Sankyo Company Limited’s price range in the past 12 months?
Daiichi Sankyo Company Limited lowest stock price was ¥3366.00 and its highest was ¥6257.00 in the past 12 months.
What is Daiichi Sankyo Company Limited’s market cap?
Daiichi Sankyo Company Limited’s market cap is $6.82T.
When is Daiichi Sankyo Company Limited’s upcoming earnings report date?
Daiichi Sankyo Company Limited’s upcoming earnings report date is Apr 24, 2025 which is in 19 days.
How were Daiichi Sankyo Company Limited’s earnings last quarter?
Daiichi Sankyo Company Limited released its earnings results on Jan 31, 2025. The company reported ¥32.82 earnings per share for the quarter, beating the consensus estimate of ¥31.472 by ¥1.348.
Is Daiichi Sankyo Company Limited overvalued?
According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued.
Does Daiichi Sankyo Company Limited pay dividends?
Daiichi Sankyo Company Limited pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.74%. See more information on Daiichi Sankyo Company Limited dividends here
What is Daiichi Sankyo Company Limited’s EPS estimate?
Daiichi Sankyo Company Limited’s EPS estimate is 19.69.
How many shares outstanding does Daiichi Sankyo Company Limited have?
Daiichi Sankyo Company Limited has 1,908,322,100 shares outstanding.
What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?
Daiichi Sankyo Company Limited reported an EPS of ¥32.82 in its last earnings report, beating expectations of ¥31.472. Following the earnings report the stock price went down -3.06%.
Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?
Currently, no hedge funds are holding shares in JP:4568
---
Company Description
Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
---
4568 Company Deck
---
4568 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a robust financial performance with significant revenue and profit growth, driven by strong product sales and successful patent settlements. However, slight downward adjustments in sales forecasts and potential financial uncertainties were noted.Read More>---
4568 Stock 12 Month Forecast
Average Price Target
¥5,633.31
▲(55.62% Upside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Takeda Pharmaceutical Co
―
Best Analysts Covering 4568
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-22.38%
reiterated a buy rating last month
Copying Seiji Wakao's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -22.38% per trade.
---